{"id":"https://openalex.org/W2066640293","doi":"https://doi.org/10.1038/bjc.2012.482","title":"Association of creatine kinase and skin toxicity in phase I trials of anticancer agents","display_name":"Association of creatine kinase and skin toxicity in phase I trials of anticancer agents","publication_year":2012,"publication_date":"2012-10-25","ids":{"openalex":"https://openalex.org/W2066640293","doi":"https://doi.org/10.1038/bjc.2012.482","mag":"2066640293","pmid":"https://pubmed.ncbi.nlm.nih.gov/23099802","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3504946"},"language":"en","primary_location":{"id":"doi:10.1038/bjc.2012.482","doi":"https://doi.org/10.1038/bjc.2012.482","is_oa":true,"landing_page_url":"https://doi.org/10.1038/bjc.2012.482","pdf_url":"https://www.nature.com/articles/bjc2012482.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","datacite","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.nature.com/articles/bjc2012482.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"V Moreno Garcia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"V Moreno Garcia","raw_affiliation_strings":["Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, 15 Cotswold Road, Sutton SM2 5NG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, 15 Cotswold Road, Sutton SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111652936","display_name":"P. Thavasu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"P Thavasu","raw_affiliation_strings":["Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]},{"raw_affiliation_string":"Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, UK","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090915955","display_name":"Montserrat Blanco Codesido","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M Blanco Codesido","raw_affiliation_strings":["Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, Sutton, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, Sutton, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK","institution_ids":["https://openalex.org/I1325846038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074632224","display_name":"Lulama Rhoda Molife","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"L R Molife","raw_affiliation_strings":["Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, Sutton, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, Sutton, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK","institution_ids":["https://openalex.org/I1325846038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044886058","display_name":"J. Vitfell-Pedersen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J Vitfell Pedersen","raw_affiliation_strings":["Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, Sutton, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, Sutton, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK","institution_ids":["https://openalex.org/I1325846038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070839902","display_name":"Martina Puglisi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M Puglisi","raw_affiliation_strings":["Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, Sutton, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, Sutton, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK","institution_ids":["https://openalex.org/I1325846038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017721654","display_name":"Bristi Basu","orcid":"https://orcid.org/0000-0002-3562-2868","observed_orcids":["https://orcid.org/0000-0002-3562-2868"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"B Basu","raw_affiliation_strings":["Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, Sutton, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, Sutton, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK","institution_ids":["https://openalex.org/I1325846038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014900661","display_name":"Krunal Jitendrakumar Shah","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"K Shah","raw_affiliation_strings":["Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, Sutton, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, Sutton, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK","institution_ids":["https://openalex.org/I1325846038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029532518","display_name":"Jhangir Iqbal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J Iqbal","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK","institution_ids":["https://openalex.org/I1325846038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J S de Bono","raw_affiliation_strings":["Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, UK","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK","institution_ids":["https://openalex.org/I1325846038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014804968","display_name":"Stan B. Kaye","orcid":"https://orcid.org/0000-0003-3318-8575","observed_orcids":["https://orcid.org/0000-0003-3318-8575"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S B Kaye","raw_affiliation_strings":["Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, UK","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK","institution_ids":["https://openalex.org/I1325846038"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032401979","display_name":"Udai Banerji","orcid":"https://orcid.org/0000-0003-1503-3123","observed_orcids":["https://orcid.org/0000-0003-1503-3123"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"U Banerji","raw_affiliation_strings":["Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, UK","The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Therapeutics and Division of Clinical Studies, Drug Development Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616"]},{"raw_affiliation_string":"Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Downs Road, Sutton, SM2 5PT, UK","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"Division of Cancer Therapeutics, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, UK","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]},{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, Drug Development Unit, Sycamore House, Sutton, UK","institution_ids":["https://openalex.org/I1325846038"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5032401979"],"corresponding_institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I142947616","https://openalex.org/I2801316944"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":{"value":5190,"currency":"USD","value_usd":5190},"fwci":2.4017,"has_fulltext":true,"cited_by_count":18,"citation_normalized_percentile":{"value":0.87866311,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"107","issue":"11","first_page":"1797","last_page":"1800"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12433","display_name":"Skin Diseases and Diabetes","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/creatine-kinase","display_name":"creatine kinase","score":0.9919999837875366},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.734000027179718},{"id":"https://openalex.org/keywords/skin-toxicity","display_name":"skin toxicity","score":0.843999981880188},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.8349999785423279},{"id":"https://openalex.org/keywords/plasma-biomarkers","display_name":"plasma biomarkers","score":0.5830000042915344},{"id":"https://openalex.org/keywords/keratinocytes","display_name":"keratinocytes","score":0.703000009059906},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.6060000061988831},{"id":"https://openalex.org/keywords/mek","display_name":"MEK","score":0.9679999947547913},{"id":"https://openalex.org/keywords/pi3k-mtor-inhibitors","display_name":"PI3K/mTOR inhibitors","score":0.8740000128746033},{"id":"https://openalex.org/keywords/creatine-kinase-isoforms","display_name":"creatine kinase isoforms","score":0.7739999890327454},{"id":"https://openalex.org/keywords/adverse-event-reporting","display_name":"adverse event reporting","score":0.6430000066757202}],"concepts":[{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.8830757141113281},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6951568126678467},{"id":"https://openalex.org/C36880943","wikidata":"https://www.wikidata.org/wiki/Q409458","display_name":"Creatine kinase","level":2,"score":0.6854972839355469},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5489559173583984},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.49822449684143066},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4876624345779419},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4605281949043274},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4376080334186554},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.42428457736968994},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3871116042137146},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.12241330742835999},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D003402","descriptor_name":"Creatine Kinase","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D005076","descriptor_name":"Exanthema","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D005076","descriptor_name":"Exanthema","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015603","descriptor_name":"Keratinocytes","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.1038/bjc.2012.482","doi":"https://doi.org/10.1038/bjc.2012.482","is_oa":true,"landing_page_url":"https://doi.org/10.1038/bjc.2012.482","pdf_url":"https://www.nature.com/articles/bjc2012482.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2818251","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3504946","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3504946","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3504946","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Br J Cancer","raw_type":"Text"},{"id":"pmid:23099802","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23099802","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of cancer","raw_type":"Journal Article"},{"id":"pmh:oai:www.repository.cam.ac.uk:1810/310738","doi":null,"is_oa":true,"landing_page_url":"https://www.repository.cam.ac.uk/handle/1810/310738","pdf_url":null,"source":{"id":"https://openalex.org/S4306401777","display_name":"Apollo (University of Cambridge)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I241749","host_organization_name":"University of Cambridge","host_organization_lineage":["https://openalex.org/I241749"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Article"},{"id":"doi:10.17863/cam.57827","doi":"https://doi.org/10.17863/cam.57827","is_oa":true,"landing_page_url":"https://doi.org/10.17863/cam.57827","pdf_url":null,"source":{"id":"https://openalex.org/S7407050737","display_name":"Apollo","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"}],"best_oa_location":{"id":"doi:10.1038/bjc.2012.482","doi":"https://doi.org/10.1038/bjc.2012.482","is_oa":true,"landing_page_url":"https://doi.org/10.1038/bjc.2012.482","pdf_url":"https://www.nature.com/articles/bjc2012482.pdf","source":{"id":"https://openalex.org/S62966998","display_name":"British Journal of Cancer","issn_l":"0007-0920","issn":["0007-0920","1532-1827"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319965","host_organization_name":"Springer Nature","host_organization_lineage":["https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Nature"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8100000023841858}],"study_designs":[],"awards":[{"id":"https://openalex.org/G3223063596","display_name":null,"funder_award_id":"C12540/A15573","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"},{"id":"https://openalex.org/G513727605","display_name":null,"funder_award_id":"C309/A8274","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"},{"id":"https://openalex.org/G6376328107","display_name":null,"funder_award_id":"C51/A6883","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"},{"id":"https://openalex.org/G789956191","display_name":null,"funder_award_id":"A309/A11566","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"}],"funders":[{"id":"https://openalex.org/F4320319985","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67"},{"id":"https://openalex.org/F4320333939","display_name":"Imperial Experimental Cancer Medicine Centre","ror":null}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2066640293.pdf","grobid_xml":"https://content.openalex.org/works/W2066640293.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W58250468","https://openalex.org/W1970668029","https://openalex.org/W1976375605","https://openalex.org/W1980209017","https://openalex.org/W1995139273","https://openalex.org/W2003806363","https://openalex.org/W2007116076","https://openalex.org/W2041686985","https://openalex.org/W2052913806","https://openalex.org/W2070044783","https://openalex.org/W2087115959","https://openalex.org/W2094544760","https://openalex.org/W2106543129","https://openalex.org/W2108517627","https://openalex.org/W2153493705","https://openalex.org/W2158134441","https://openalex.org/W2413422691","https://openalex.org/W2443756068","https://openalex.org/W2520717841","https://openalex.org/W2591434114","https://openalex.org/W4256664559"],"related_works":["https://openalex.org/W7097220239","https://openalex.org/W4403904809","https://openalex.org/W1992944444","https://openalex.org/W6939919462","https://openalex.org/W1993917607","https://openalex.org/W2582112348","https://openalex.org/W2511342761","https://openalex.org/W2489178714","https://openalex.org/W2971693037","https://openalex.org/W2099090698"],"abstract_inverted_index":{"BACKGROUND:":[0],"We":[1,20],"investigated":[2],"the":[3,40,82,120,152,191],"association":[4],"between":[5],"skin":[6,171],"rash":[7,92,106,121,172],"and":[8,62,104,146,157],"plasma":[9,79],"creatine":[10],"kinase":[11,68],"(CK)":[12],"levels":[13,77],"in":[14,39,117,128,197],"oncology":[15,198],"phase":[16,32,199],"I":[17,33,200],"trials.":[18,202],"METHODS:":[19],"analysed":[21],"data":[22],"from":[23],"295":[24],"patients":[25,87],"treated":[26],"at":[27],"our":[28],"institution":[29],"within":[30],"25":[31,129],"trials":[34],"which":[35],"included":[36],"CK":[37,80,118,133,164],"measurements":[38,69],"protocol.":[41],"Trials":[42],"involved":[43],"drugs":[44],"targeting":[45],"EGFR/HER2,":[46],"m-TOR,":[47],"VEGFR,":[48],"SRC/ABL,":[49],"aurora":[50],"kinase,":[51],"BRAF/MEK,":[52],"PARP,":[53],"CDK,":[54],"A5B1":[55],"integrin,":[56],"as":[57,59,187],"well":[58],"oncolytic":[60],"viruses":[61],"vascular":[63],"disrupting":[64],"agents.":[65,177],"RESULTS:":[66],"Creatine":[67],"were":[70,84,135],"available":[71],"for":[72],"278":[73],"patients.":[74],"The":[75],"highest":[76],"of":[78,140,155,170],"during":[81],"trial":[83],"seen":[85],"among":[86],"with":[88,98,168],"Grade":[89],"(G)":[90],"2/3":[91],"(median":[93,100,107],"249":[94],"U":[95,102,109],"l(-1))":[96,103,110],"compared":[97],"G1":[99],"81":[101],"no":[105],"55":[108],"(P<0.001).":[111],"There":[112],"was":[113],"a":[114,147],"significant":[115],"reduction":[116],"after":[119],"resolved":[122],"(mean":[123],"264.2":[124],"vs":[125],"100.1;":[126],"P=0.012)":[127],"patients,":[130],"where":[131],"serial":[132],"values":[134],"available.":[136],"In":[137],"vitro":[138],"exposure":[139],"human":[141],"keratinocytes":[142],"to":[143,151,183],"EGFR,":[144],"MEK":[145],"PI3Kinase/m-TOR":[148],"inhibitor":[149],"led":[150],"increased":[153],"expression":[154],"CK-brain":[156],"not":[158],"CK-muscle":[159],"or":[160],"mitochondrial-CK.":[161],"CONCLUSION:":[162],"Plasma":[163],"elevation":[165],"is":[166],"associated":[167],"development":[169],"caused":[173],"by":[174],"novel":[175],"anticancer":[176],"This":[178],"should":[179],"be":[180],"studied":[181],"further":[182],"characterise":[184],"different":[185],"isoforms":[186],"this":[188],"will":[189],"change":[190],"way":[192],"we":[193],"report":[194],"adverse":[195],"events":[196],"clinical":[201]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}